Browsing Tag
HRS-1596
2 posts
Novo Nordisk licenses Hengrui weekly oral GLP-1/GIP drug in deal worth up to $2.6bn
HRS-1596 adds an oral GLP-1/GIP dual agonist to Novo Nordisk’s external pipeline only days after the company licensed technology aimed at monthly and quarterly injections.
Hengrui lands $2.6bn Novo Nordisk deal for experimental weekly oral obesity drug
Novo Nordisk licenses Hengrui’s weekly oral GLP-1/GIP drug HRS-1596 for up to $2.6 billion as obesity competition intensifies.